Related Experiment Video
Updated: Sep 12, 2025
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
Published on: October 14, 2021
Calcinosis Universalis: An Atypical Presentation of Mi-2 Positive Juvenile Dermatomyositis - A Case-Based Review
Rajat Kumar Sahu1, Abhishek Gollarahalli Patel1, Rajat Gupta1
1Department of Clinical Immunology and Rheumatology, King George's Medical University, Lucknow, India.
Insights
This case highlights a rare instance of Juvenile Dermatomyositis (JDM) with calcinosis and anti-Mi-2 antibodies. Early treatment with tofacitinib and pamidronate prevented new calcinosis formation, suggesting personalized strategies are key.
Area of Science:
- Pediatric Rheumatology
- Autoimmune Diseases
- Dermatology
Background:
- Juvenile Dermatomyositis (JDM) is a rare autoimmune disease affecting children, causing skin and muscle inflammation.
- Calcinosis occurs in a significant portion of JDM patients, leading to severe complications.
- The co-occurrence of calcinosis and anti-Mi-2 antibodies in JDM is exceptionally rare and challenging to manage.
Purpose of the Study:
- To report a unique case of JDM with extensive calcinosis and anti-Mi-2 antibodies.
- To review the literature on this rare association and its management.
- To discuss potential therapeutic strategies for such complex cases.
Main Methods:
- Case presentation of a 12-year-old girl with JDM, calcinosis, and anti-Mi-2 antibodies.
- Review of existing medical literature on JDM, calcinosis, and anti-Mi-2 antibodies.
- Analysis of treatment outcomes including tofacitinib and intravenous pamidronate.
Main Results:
- The patient presented with severe muscle weakness, skin issues, and contractures due to calcinosis.
- Initial treatment with tofacitinib and pamidronate halted the progression of new calcinosis.
- Literature review confirmed the rarity of calcinosis in anti-Mi-2 positive JDM patients.
Conclusions:
- This case underscores the importance of recognizing and managing rare presentations of JDM.
- Personalized treatment approaches are essential for optimizing outcomes in JDM with calcinosis and specific antibodies.
- Further research into novel therapies, such as JAK inhibitors, is warranted for refractory cases.
Background:
Juvenile Dermatomyositis (JDM) is a systemic autoimmune disease in children, characterised by skin and muscle inflammation, with incidence of 1.6 to 4 cases per million children annually. Calcinosis, affecting 20% to 70% of JDM patients, can lead to significant morbidity. The association of calcinosis with anti-Mi-2 antibodies is rare and complicates management.
Case:
We present a rare case of a 12-year-old girl diagnosed with JDM, extensive calcinosis, and positive anti-Mi-2 antibodies. The patient exhibited significant muscle weakness, skin manifestations, and painful calcinosis leading to contractures. Initial management included tofacitinib and intravenous pamidronate, resulting in no new calcinosis formation.
Discussion:
A comprehensive review of existing literature highlights the rarity of calcinosis in anti-Mi-2 positive patients. While traditional treatments have shown variable effectiveness, emerging therapies like JAK (Janus Kinase) inhibitors may offer new avenues for management. The literature underscores the need for personalised treatment strategies given the atypical presentations and outcomes.
Conclusion:
This case adds to the limited documentation of calcinosis in JDM with anti-Mi-2 antibodies, emphasising the need for increased awareness and research. Personalised treatment approaches are crucial, and future studies should focus on larger datasets and emerging therapeutic modalities to optimise management and improve patient outcomes.
More Related Videos
10:27Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
Published on: December 15, 2011
08:43Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
Published on: May 31, 2016
Related Concept Videos
01:27Myocarditis II: Clinical Features and Diagnostic Tests
01:11Papillary Dermis
The dermis might be considered the "core" of the integumentary system, as distinct from the epidermis and hypodermis. It contains blood and lymph vessels, nerves, and other structures, such as hair follicles and sweat glands. The dermis is made of two layers of connective tissue that comprise an interconnected mesh of elastin and collagenous fibers, produced by fibroblasts.
Papillary Layer
The papillary layer is made of loose, areolar connective tissue, which means the collagen...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:25Endocarditis II: Clinical Features of Infective Endocarditis
01:15Reticular Dermis
Reticular Layer
Underlying the papillary layer is the much thicker reticular layer, composed of dense, irregular connective...
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...